Vertex unveils promising VX-222/Incivek combo data in HCV
This article was originally published in Scrip
Executive Summary
Vertex Pharmaceuticals has no plans to rest on its laurels in the treatment of HCV. Hot on the heels of getting FDA approval for Incivek (telaprevir), the oral HCV protease inhibitor developed in collaboration with the Janssen Pharmaceutical company Tibotec Virco (scripintelligence.com, 23 May 2011), the company has unveiled interim Phase II data highlighting the potential of VX-222, its lead hepatitis C virus polymerase inhibitor, as part of a combination approach to treating genotype-1 hepatitis C.